The National Heart Lung & Blood Institute (NHLBI) and the National Cancer Institute (NCI) are seeking research co-development partners and/or licensees for a novel technology: a newly developed method of obtaining hyperpolarized imaging agents for real-time metabolic imaging using magnetic resonance imaging (MRI). This method, catalyst and the resulting imaging agents, can be used in MRI metabolic imaging to detect cancer, cardiovascular disease, stroke, and traumatic brain injury; and monitor therapies without the presence of metals such as gadolinium or iron.  Learn about this new technology by attending a free webinar on December 18th and hear from Rolf Swenson, Ph.D., the co-inventor.

Potential Commercial Applications:

• MRI imaging
• Hyperpolarization (a technique that has many applications)
• Infusion Device for imaging reagents
• Cancer diagnostics
• Cardiovascular disease diagnostics
   

Competitive Advantages:

• Fast cycle times; (hyperpolarized pyruvate obtained in one minute with SABRE catalyst versus hours by traditional means).
  Recyclable over many hyperpolarization cycles.
• Maintains catalytic activity over many hyperpolarization cycles.
• Low production costs.
• SABRE process eliminates the need for gadolinium or iron.

Who should attend?

• Business development professionals
• Parties interested in scouting for technologies to improve MRI outcomes
• Biotech/pharma/academia researchers
• Investors and entrepreneurs

Why attend?

• Assess co-developing the technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with NIH and NHLBI facilitated by the NCI Technology Transfer Center

For more information on this technology, please view the abstract: Next Generation MRI Platform Signal Amplification by Reversible Exchange (SABRE) Hyperpolarization 

For registration and further information on the webinar, please visit the NCI Technology Transfer website.